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Abstract Cortical microinfarcts (CMIs) observed in
brains of patients with Alzheimer’s disease tend to be
located close to vessels afﬂicted with cerebral amyloid
angiopathy (CAA). CMIs in Alzheimer’s disease are
preferentially distributed in the arterial borderzone, an area
most vulnerable to hypoperfusion. However, the causal
association between CAA and CMIs remains to be eluci-
dated. This study consists of two parts: (1) an observational
study using postmortem human brains (n = 31) to deter-
mine the association between CAA and CMIs, and (2) an
experimental study to determine whether hypoperfusion
worsens CAA and induces CMIs in a CAA mouse model.
In postmortem human brains, the density of CMIs was
0.113/cm
2 in mild, 0.584/cm
2 in moderate, and 4.370/cm
2
in severe CAA groups with a positive linear correlation
(r = 0.6736, p\0.0001). Multivariate analysis revealed
that, among seven variables (age, disease, senile plaques,
neuroﬁbrillary tangles, CAA, atherosclerosis and white
matter damage), only the severity of CAA was a signiﬁcant
multivariate predictor of CMIs (p = 0.0022). Consistent
with the data from human brains, CAA model mice fol-
lowing chronic cerebral hypoperfusion due to bilateral
common carotid artery stenosis induced with 0.18-mm
diameter microcoils showed accelerated deposition of
leptomeningeal amyloid b (Ab) with a subset of them
developing microinfarcts. In contrast, the CAA mice
without hypoperfusion exhibited very few leptomeningeal
Ab depositions and no microinfarcts by 32 weeks of age.
Following 12 weeks of hypoperfusion, cerebral blood ﬂow
decreased by 26% in CAA mice and by 15% in wild-type
mice, suggesting impaired microvascular function due to
perivascular Ab accumulation after hypoperfusion. Our
results suggest that cerebral hypoperfusion accelerates
CAA, and thus promotes CMIs.
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Introduction
Cortical microinfarcts (CMIs) are frequently observed in
the brains of Alzheimer’s disease (AD) patients [33, 41],
and tend to be located in the vascular territory of lepto-
meningeal arteries or cortical arterioles exhibiting cerebral
amyloid angiopathy (CAA), a pathological hallmark of AD
[20, 33]. Furthermore, CMIs in AD are preferentially dis-
tributed in the arterial borderzone, an area particularly
vulnerable to hypoperfusion [41], suggesting a causal
relationship between CAA and CMIs, with hypoperfusion
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DOI 10.1007/s00401-011-0925-9serving as a mediating factor. Indeed, our neuropatho-
logical study has shown that CMIs are present
predominantly in the arterial borderzone between the
middle and posterior cerebral artery territories in AD
patients [33], which may coincide with the relative predi-
lection of CAA pathology in posterior brain regions [42].
Nevertheless, the previous reports on the association
between CAA and CMIs in AD brains have been con-
ﬂicting [12, 24, 34, 40]; some studies have reported an
association [34, 40] while others have found no such link
[12, 24] (Supplementary Table 1). One of the plausible
explanations for the disparity in the previous reports is the
difﬁculty in assessing how the various AD-related pathol-
ogies, such as senile plaques (SPs), neuroﬁbrillary tangles
(NFTs), and CAA contribute to CMI development. Another
complication arising from the ﬁndings is that these patho-
logical changes can also be interdependent on concomitant
atherosclerosis or arteriolosclerosis [34, 46]. Such difﬁ-
culties are exempliﬁed by the fact that SPs and CAA
appear in close proximity in AD patients [48], though on a
case-by-case level, an inverse correlation between CAA
and plaque density is apparent [50].
The purpose of this study was to elucidate the possible
association between the burden of CMIs and CAA by
investigating postmortem brains exhibiting CAA where the
ﬁnal neuropathological diagnoses included not only AD but
also other neurodegenerative disorders and vascular cog-
nitive impairment. By avoiding a biased selection of
postmortem brains, we anticipated this study would enable
comparison of AD and non-AD patients that are accom-
panied by pathologically proven CAA to investigate the
association between CMIs and CAA.
To explore whether chronic cerebral hypoperfusion is
associated with the relationship between CMIs and CAA,
we used a transgenic mouse CAA model that expresses
human vasculotropic Swedish/Dutch/Iowa mutant amyloid
precursor protein (APP) (Tg-SwDI mice) [11] and sub-
jected them to bilateral common carotid artery stenosis
(BCAS) to mimic chronic cerebral hypoperfusion [37]. By
combining the animal investigations with postmortem
human work, we aimed to reveal the underlying mecha-
nisms in the relationship between CMIs and CAA.
Materials and methods
Postmortem human brain material
Two hundred seventy-ﬁve autopsied brains were obtained
from Kyoto University Hospital and Osaka Saiseikai
Nakatsu Hospital from 1992 to 2009 through a process
approved by an institutional research committee. As we
described previously [1, 21], neuropathological diagnoses
were made by thorough histopathological examination of
extensively sampled brain sections (Supplementary Fig. 1).
In brief, in all brains at least 20 different samples, including
anteroinferior frontal region, anterior cingulate region,
middle frontal gyrus, superior frontal gyrus, precentral
gyrus, superior and middle temporal gyri, amygdala, hip-
pocampus, entorhinal cortex, supramarginal sulcus,
occipital lobe, basal ganglia, thalamus, cerebellum, and at
least 3 levels of the brainstem, were systematically taken
from the formalin-ﬁxed brains (Supplementary Fig. 1).
Among the 275 patients, 31 patients were pathologically
proved to have CAA by hematoxylin and eosin (H&E)
staining and then by b-amyloid (Ab) immunostaining, all
of which were included in this study. Autopsies were
performed at 12.9 ± 11.9 h (mean ± SD) (range 1.5–
45.5 h) after death. The average ﬁxation time was 37 ±
57 days (range 6–330 days) (Supplementary Table 2).
Clinical and pathological diagnosis
The 31 patients consisted of 14 AD (mean ± SD, 81 ±
8-year old) and 17 non-AD patients (78 ± 8-year old). The
breakdown of the 17 non-AD patients is listed in Supple-
mentary Table 2. The premortem clinical diagnoses, causes
of death, vascular risk factors, postmortem pathological
diagnoses and other demographic and pathological data of
the 31 patients are also shown in Supplementary Table 2.
The clinical diagnosis of dementia met the criteria of the
Diagnostic and Statistical Manual of Mental Disorders IV
[3]. The neuropathological diagnoses of AD were made if
the postmortem brains revealed the presence of frequent
neuritic plaques in the neocortex (Consortium to Establish
a Registry for Alzheimer’s Disease, CERAD) [29], and
NFT stage was no less than IV, according to the Braak and
Braak neuropathological staging of Alzheimer-related
changes [7, 8] as assessed with modiﬁed Bielschowsky
staining. Two observers (T.Y. and Y.O.) assessed SP and
NFT stage individually, and if required, a joint assessment
was scrutinized under a two headed microscope. The
diagnosis of diffuse Lewy body disease was also made by
thorough histopathological examination of extensively
sampled brain sections [27]. The diagnosis of subcortical
ischemic vascular dementia was made clinically [5], and
was retrospectively found to meet the pathological criteria
outlined by Kalaria et al. [19]: (1) the presence of bilateral
diffuse white matter lesions, (2) the presence of lacunar
infarctions in the perforator territory, and (3) the presence
of arteriolosclerosis.
Grading of atherosclerosis
Atautopsy,theatherosclerosisstagewasconsistentlygraded
byoneoftheauthors(T.Y.).Thedegreeofatherosclerosisat
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123skull base was classiﬁed into four grades: ‘normal’ (no ath-
erosclerosis), ‘mild’ (the presence of patchy atheroma),
‘moderate’ (a severity that is intermediate between mild and
severe), or ‘severe’ (the presence of atheroma along the
entire length of the vessels). The above staging was
re-examined and conﬁrmed by another author (Y.O.) using
theautopsyreportandmacroscopicimagestakenatautopsy.
Tinctorial and immunohistochemical staining
Tissue blocks were obtained from the frontal, temporal,
parietal, and occipital lobes (Supplementary Fig. 1). The
blocks were embedded in parafﬁn and sectioned at 12 lm
thickness for Congo Red staining, and 6 lm thickness for
other staining on a microtome. To minimize variability in
staining intensity, tissue sections were prepared by the same
technician and stained with or using freshly prepared tinc-
torial and buffer solutions. Routine histological assessment
was carried out with Congo Red, H&E, Klu ¨ver-Barrera
(KB), modiﬁed Bielschowsky, and Gallyas staining. Pearls-
Stieda staining was added as it was needed. The rest of the
blocks were used for immunohistochemistry, involving
sequential incubation with primary antibody, appropriate
biotinylated secondary antibody (diluted 1:200, Vector
Laboratories, Burlingame, CA, USA), and avidin–biotin–
peroxidase complex (1:200, Vector Laboratories) in 0.1 M
phosphate-buffered saline (PBS, pH 7.4). The sections were
visualizedwith 0.01% diaminobenzidine tetrahydrochloride
and0.005%H2O2in50 mMTris–HCl(pH7.6).Theprimary
antibodies were mouse anti-Ab8–17 (6F/3D) (1:100, Novo-
castra,Newcastle,UK),rabbitanti-cowglialﬁbrillaryacidic
protein(GFAP)(1:200,DAKO,Glostrup,Denmark),mouse
anti-humanpairedhelicalﬁlament-tau(AT8;1:200,Thermo
Scientiﬁc, Rockford, IL, USA), and mouse anti-cluster of
differentiation 68 (CD68) (1:100, DAKO) antibodies.
Senile plaque and neuroﬁbrillary tangle burden
The burden of neuritic plaques was classiﬁed into ‘none’,
‘sparse’, ‘moderate’, and ‘frequent’ categories in the cortical
sections stained with the modiﬁed Bielschowsky staining
according to CERAD protocol [29]. The stage of NFTs was
assessedaccording to the Braak and Braak neuropathological
staging of Alzheimer-related changes [7, 8]. In this study, we
used 6 lm thick parafﬁn sections using the modiﬁed Biels-
chowsky method as we have previously reported [52];
because, the modiﬁed Bielschowsky method is far more
effectiveoverothersilverstainingmethodsindetectingNFTs.
Staging of CAA
For staging of CAA, 12 lm thick sections were stained
with Congo Red and viewed with polarized light [13, 42].
CAA was classiﬁed into CAA Type 1 (affected capillaries
with or without larger cerebral vessel involvement) and
CAA Type 2 (affected leptomeningeal arteries, cortical
arteries/arterioles, or rarely veins), as proposed by Attems
et al. [4]. CAA Type 2 was further analyzed, and was
divided into three grades proposed by Vonsattel et al. [44]:
those with ‘mild’ (focal Ab deposits in the smooth muscle
layer of the vessel walls), ‘moderate’ (circumferential Ab
deposits in the smooth muscle layer of the vessel walls),
and ‘severe’ (extensive Ab deposition with morphological
changes such as microaneurysms, ﬁbrinoid necrosis, dou-
ble barreling, inﬂammation, thrombus, or hemorrhage)
(Fig. 1). When several grades were observed in one case,
the dominant grade represented the case.
Deﬁnition and quantitative analysis of CMI
CMIs were analyzed in the same sections that were used
for pathological conﬁrmation of CAA. CMIs were deﬁned
as cerebral cortex lesions visible only microscopically [19]
and usually accompanied by reactive glial proliferation.
Regions of interest with evidence of expanded Virchow-
Robin space or microabscess as well as those accompanied
by hemorrhagic changes or cortical laminar necrosis on
H&E staining were excluded from analysis. Following
further conﬁrmation of CMIs with immunohistochemistry
for GFAP and CD68, we determined the density of CMIs
using a method reported previously [33]. In brief, the
number of CMIs in each lobe was counted in sections
stained with H&E. Images of the H&E stained slides were
scanned (GT-X770 EPSON, Nagano, Japan). The cerebral
cortices were outlined on each slide and the areas were
measured using the ImageJ software package (image pro-
cessing and analysis in JAVA, ImageJ bundled with JAVA
1.43, NIH, USA). The number of CMIs per cm
2 of the
cortex was calculated as a measure of CMI density.
The CMI density in the frontal cortex was the mean of the
values obtained from the ﬁve areas (anteroinferior frontal
region, anterior cingulate region, middle frontal gyrus,
superior frontal gyrus, precentral gyrus), and that in the
temporal cortex was the mean of the values obtained from
the two areas (lateral and medial temporal). The CMI
density in the parietal cortex was obtained from the parietal
supramarginal gyrus, and that in the occipital cortex was
obtained from the occipital calcarine cortex (Supplemen-
tary Fig. 1).
Assessment of white matter changes
Using H&E- and KB-stained slides cut coronally at the
level of mid-hippocampus, parietal, and occipital lobes, we
classiﬁed white matter lesions into four grades as reported
previously [9, 17]: those with ‘normal’ (normal white
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123matter), ‘mild’ (no appreciable reduction in axonal mesh-
work density, and a slightly increased number of reactive
astrocytes), ‘moderate’ (a slight reduction of axonal
meshwork density, a reduction of oligodendroglial cell
nuclei, and a further increased number of reactive astro-
cytes), and ‘severe’ (a marked reduction of myelin, axons
and oligodendroglial cell nuclei with relatively marked
astrocytic reaction, loosely scattered macrophages but no
complete cerebral infarction).
Experimental animals
We used transgenic mice, C57BL/6-Tg(Thy1-APPSwDu-
tIowa)BWevn/J [11] (Jackson Laboratory, Bar Harbor,
ME, USA), which overexpress the neuronally derived
human APP gene, encoding the Swedish p.K670N/M671L,
Dutch p.E693Q and Iowa p.D694N mutations, under the
control of the mouse thymus cell antigen 1 (Thy1) pro-
moter. Generally, Thy1-driven exogenous gene expression
is not altered by hypoxic/ischemic condition [26, 43]. The
mice were screened for transgene expression by polymer-
ase chain reaction, and heterozygous mice were mated
with non-transgenic C57BL/6J mice (Japan SLC, Ham-
amatsu, Japan). All mice were given free access to food
and water.
Surgical procedures and rearing methods
Male heterozygous mice were subjected to either sham or
BCAS operation using microcoils [22, 30, 32, 37, 38].
Body weight and rectal temperature were measured, and
blood pressure was monitored from the tail artery of the
sham- or BCAS-operated mice. Under anesthesia with
1.5% isoﬂurane, the common carotid arteries were exposed
through a midline cervical incision, and a microcoil with an
internal diameter of 0.18 mm was applied to the bilateral
common carotid arteries. Sham-operated animals under-
went bilateral exposure of the common carotid arteries
without inserting the microcoil. Rectal temperature was
maintained between 36.5 and 37.5C, and body weight
monitored until the animals were euthanized. After the
operation, the mice were housed in cages with a 12-h light/
dark cycle (lights on at 7:00 a.m.). Three animal groups
were prepared in this experiment (6 groups, n = 4–7 per
group, n = 31 in total; detailed information given in
Supplementary Table 3). The timing of sham/BCAS and
the duration of cerebral hypoperfusion are described in
Supplementary Fig. 2. In brief, Tg-SwDI mice were sub-
jected to sham or BCAS operation at 10, 16, and 20 weeks
of age, and they were subsequently killed at 18, 24, and
32 weeks of age, respectively, to assess histology. Wild-
type age-matched C57BL/6J mice (n = 5 per group) were
also subjected to BCAS operation. The number of mice
used in this study was minimized for ethical reasons, and
all procedures were performed in accordance with the
guidelines for animal experimentation from the ethical
committee of Kyoto University.
Systolic blood pressure and cerebral blood ﬂow
measurements
Mice were thermostatically controlled at 37Co na
warming pad and cerebral blood ﬂow (CBF) and systolic
blood pressure (SBP) recorded preoperatively and postop-
eratively at 32 weeks of age (12 weeks after BCAS or
sham operation). Mean value of ten replicate measurements
of CBF or SBP was determined for each mouse. The SBP
was monitored in conscious mice by the tail-cuff method
(MK-2000ST; Muromachi Co., Kyoto, Japan). The CBF
was measured in identically sized regions of interest (900
pixels) located 1 mm posterior and 2 mm lateral from the
bregma by Laser speckle blood ﬂow imager (Omega Zone;
Omegawave, Tokyo, Japan) under anesthesia with 1.5%
isoﬂurane after the periosteum was widely removed with
ﬁne-tip forceps and calibration was carried out with a
calibration reference device (Calibrator S/N 080715-5,
Omegawave, Inc., Tokyo, Japan). CBF values were
expressed as a percentage of the preoperative value. Since
Fig. 1 Representative photomicrographs of various grades of CAA. Congo Red staining showing mild CAA (a), moderate CAA (b), and severe
CAA associated with double barreling (c). Bars indicate 100 lmi na and c, and 50 lmi nb
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123repetitive CBF measurement leads to ﬁbrous scar tissue
build up and bone opaciﬁcation, CBF was measured only at
two time points.
Histological investigation in mice
Mice were anesthetized with sodium pentobarbital
(50 mg/kg, intraperitoneal) and transcardially perfused
with 0.01 M phosphate buffer (PB) in normal saline. The
removed brains were immersion-ﬁxed in 4% paraformal-
dehyde in 0.1 M PB, and embedded in parafﬁn. The brains
were then sliced into 6 lm thick sagittal sections at 1, 2, 3,
and 4 mm lateral from the midline, and subjected to H&E
and modiﬁed Bielschowsky staining. Immunohistochemi-
cal staining was performed according to the same protocol
as human tissue. Mouse anti-Ab1–40 (BA27) (Wako amy-
loid kit, Wako, Osaka, Japan), mouse anti-Ab1–42 (BC05)
(Wako amyloid kit, Wako), and mouse anti-Ab5–10 (6E10)
(1:500, Covance, Princeton, NJ, USA) antibodies were
used.
Densitometric analysis of mouse brains
The Ab-stained slides were captured with a digital camera
(BZ-9000 KEYENCE, Osaka, Japan). Then, using the
ImageJ software, the densitometric analysis of Ab was
performed blindly to animal groups by setting regions of
interest in the cerebral cortex, the hippocampus, and the
leptomeninges with the identical threshold in the Ab
(6E10)-immunostained sections. Leptomeningeal vascular,
as well as pial, Ab accumulations were jointly analyzed as
‘leptomeningeal Ab’.
Statistical analysis
For human samples, numerical scores were computed from
the data analysis as follows: age, 65- to 93-year old;
disease group, AD = 1 or non-AD = 0; the grade of ath-
erosclerosis, 0–3; the severity of CAA, 1–3; SP burden,
0–3; NFT stage, 0–6; and the grade of WML, 0–3. We ﬁrst
performed univariate analysis to determine whether age,
disease type, or the above pathological changes were pre-
dictive of CMI formation using Fisher’s exact test. Next,
multivariate analysis was performed while taking into
account the effects of all variables on the parameters
measured, including CMI formation.
In mice, Student’s t test was used to evaluate possible
differences between the sham- and BCAS-operated mice
groups at each time point, and two-way ANOVA was used
to test for the effect of age and operation on Ab deposition
in the hippocampus, cerebral cortex, and leptomeninges.
Differences with p\0.05 were considered statistically
signiﬁcant in all analyses used.
Results
The grade of CAA and atherosclerosis, SP and NFT stage,
the degree of WML, and the CMI densities in the autopsy
series are shown in Table 1.
Capillary CAA
Capillary CAA was found in only one patient (Table 1,
Patient no. 26). In this patient, ﬁndings of Ab depositions
in the leptomeningeal arteries and cortical arterioles were
also prominent. In the remaining 30 patients, capillary
CAA was undetectable with H&E staining and Ab
immunohistochemistry. In the following analyses, there-
fore, only CAA Type 2 was graded.
Cortical microinfarcts
CMIs were present along the sulcus in the superﬁcial
cortex with variable frequency among the postmortem
brains (Fig. 2a, b). The average microinfarct diameter was
approximately 200 lm (range 100–500 lm). Some lesions
were recently formed, with the presence of GFAP-positive
gemistocytic astroglial cells and CD68-positive microglia/
macrophages (Fig. 2c–e), while others were relatively old
with induction of ﬁbrillary astrocyte gliosis. Thrombus
formation was found in one patient with severe CAA
(Table 1, Patient no. 13).
Most CMIs ([90%) were located in close proximity
(*1 cm) to Ab-deposited vessels (Fig. 3a–c). Around
ischemic foci, such as CMIs or necrosis, SPs were some-
times not present (Fig. 3c). Furthermore, in and around
ischemic foci, vascular Ab deposition appeared to increase
in intensity (Fig. 3a–c).
CMI density in AD and non-AD patients
The results of the univariate analyses are shown in Table 2.
The mean CMI density within the four cortical lobes was
not signiﬁcantly different (r =- 0.1007, p = 0.5900) in
AD group (0.71/cm
2) and non-AD group (1.12/cm
2)
(Fig. 4a). When AD and non-AD groups were combined,
CMI density in the frontal, temporal, parietal, and occipital
lobes was 1.02, 0.65, 1.18, and 0.93/cm
2, respectively
(Fig. 4b). There were no signiﬁcant differences in the CMI
density within the four cortical lobes. CMI density in the
frontal, temporal, parietal, and occipital lobes was 1.32,
0.29, 1.03, and 0.30/cm
2, respectively, in the AD group,
while in the non-AD group the CMI density was 0.76, 0.97,
1.29, and 1.44/cm
2, respectively (Fig. 4c).
CMI density was 0.11/cm
2 in mild, 0.58/cm
2 in mod-
erate, and 4.37/cm
2 in severe CAA groups, meaning it
became greater as CAA severity increased (r = 0.6736,
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123p\0.0001) (Fig. 4d). This CAA–CMI correlation was
observed in all lobes (Fig. 4e); the r value was 0.6377 in
the frontal lobe (p = 0.0014), 0.5676 in the temporal lobe
(p = 0.0055), 0.5355 in the parietal lobe (p = 0.0078), and
0.5652 in the occipital lobe (p = 0.0033). Such CAA–CMI
correlation was also observed in both disease groups (AD
or non-AD) (Fig. 4f). CMI density was not associated with
SP burden (r =- 0.2265, p = 0.2204) (Fig. 4g), or NFT
stage (r =- 0.1378, p = 0.4597) (Fig. 4h). Thus, CMI
density did not change with greater burden of SP or NFT.
CMI density was also not associated with the grade of
atherosclerosis (r =- 0.0913, p = 0.6312) (Fig. 4i).
The results of the multivariate analysis are shown in
Table 3. The severity of CAA was a signiﬁcant multivar-
iate predictor (p = 0.0022), with a standard partial
regression coefﬁcient of 0.6395. Similar trends were evi-
dent in each lobe (frontal, p = 0.0014; temporal,
p = 0.0055; parietal, p = 0.0078; occipital, p = 0.0033).
However, age (p = 0.5979), the grade of atherosclerosis
(p = 0.3973), AD or non-AD (p = 0.8364), SP burden
(p = 0.5164), NFT stage (p = 0.3870), or the grade of
WML (p = 0.6931) were not signiﬁcant multivariate
predictors.
Cerebral blood ﬂow in mice after BCAS
The BCAS operation reduced CBF by 15% in 20-week-old
wild-type mice and 26% in Tg-SwDI mice of the same age
after 12 weeks with a statistically signiﬁcant difference
(p = 0.0412) (Supplementary Fig. 3).
Table 1 Detailed pathological analysis of 31 patients with cerebral amyloid angiopathy
No. Age Gender AD or non-AD Grade of atherosclerosis
at skull base
CAA SP NFT CMI density (/cm
2) WML
FT PO
1 85 M AD Moderate Mild Frequent IV 0.00 0.00 0.00 0.00 Mild
2 82 F AD Mild Mild Frequent IV 0.00 0.40 – 0.20 Normal
3 76 F AD ND Mild Frequent IV 0.51 0.00 0.00 0.00 Moderate
4 86 F AD Mild Mild Frequent IV 0.00 0.26 0.47 0.00 Mild
5 80 F AD Mild Mild Frequent V 0.45 0.00 0.54 0.00 Moderate
6 67 F AD Mild Mild Frequent VI 0.00 0.00 0.31 0.00 Mild
7 84 F AD Mild Mild Frequent VI 0.09 0.00 0.00 0.00 Normal
8 68 M AD Mild Moderate Frequent IV 0.00 0.00 0.00 0.00 Mild
9 93 F AD Moderate Moderate Frequent VI 0.71 0.00 0.00 0.00 Mild
10 84 F AD Moderate Moderate Frequent V 0.00 0.26 0.00 0.00 Moderate
11 91 M AD Mild Moderate Frequent IV 0.64 0.30 0.55 0.11 Severe
12 85 F AD Moderate Moderate Frequent V 1.55 0.55 7.01 0.00 Mild
13 83 M AD Normal Severe Frequent IV 12.6 1.49 0.31 2.31 Moderate
14 71 M AD Mild Severe Frequent IV 2.00 0.47 4.18 1.58 Mild
15 90 M Non-AD Mild Mild Sparse IV 0.00 0.00 0.00 0.00 Moderate
16 66 M Non-AD Severe Mild Sparse II 0.00 0.00 0.00 0.29 Normal
17 83 F Non-AD Mild Mild Sparse IV 0.00 0.00 0.42 0.00 Moderate
18 84 M Non-AD Mild Mild Sparse I 0.00 0.00 0.24 0.00 Mild
19 76 M Non-AD Mild Mild Sparse I 0.45 0.00 0.00 0.00 Mild
20 90 F Non-AD Mild Mild Moderate IV 0.11 0.00 0.93 0.31 Mild
21 86 M Non-AD Mild Mild Moderate IV 0.00 0.24 0.23 0.00 Moderate
22 84 F Non-AD Mild Mild Moderate II 0.00 0.00 0.29 0.50 Mild
23 65 M Non-AD Normal Mild Frequent V 0.00 0.00 0.00 0.00 Normal
24 81 M Non-AD Mild Mild Frequent V 0.20 0.00 0.00 0.00 Moderate
25 72 M Non-AD Moderate Moderate Sparse II 0.00 1.45 0.32 0.00 Moderate
26 75 M Non-AD Severe Moderate Sparse II 0.19 2.59 1.22 0.33 Mild
27 73 F Non-AD Mild Moderate Sparse II 0.19 0.00 0.00 0.00 Mild
28 82 M Non-AD Normal Moderate Moderate II 0.49 0.00 0.38 2.17 Mild
29 71 M Non-AD Moderate Severe None II 2.55 2.65 3.56 0.94 Mild
30 72 F Non-AD Mild Severe Sparse II 2.33 1.10 1.66 6.26 Mild
31 69 F Non-AD Mild Severe Sparse III 6.48 8.48 12.8 13.7 Moderate
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123Histological ﬁndings in Tg-SwDI mice
We found that microinfarcts developed in a subset of
BCAS-operated Tg-SwDI mice (Fig. 5). The percentage of
BCAS-operated Tg-SwDI mice (n = 17) exhibiting micr-
oinfarcts was 33.3 (2 out of 6), 42.9 (3 out of 7) and 25.0%
(1 out of 4) at 18, 24, and 32 weeks of age. However,
microinfarcts were not found in sham-operated Tg-SwDI
mice (n = 14) or BCAS-operated wild-type mice (n = 15)
up to 32 weeks of age. The number of microinfarcts in
BCAS-operated Tg-SwDI mice, sham-operated Tg-SwDI
mice, and BCAS-operated wild-type mouse was listed in
Supplementary Table 3. Immunohistochemical analysis
showed that ischemic insults accelerated perivascular and
leptomeningeal Ab accumulations (Fig. 6a, b). Generally,
the immunostained patterns of Ab1–40 and Ab1–42 were
quite similar, although Ab40 immunostaining was more
intense than Ab1–42, in accordance with a previous bio-
chemical study [11]. Ab accumulation was evident in and
around microvessels as well as larger cerebral vessels
(approximately 10–15 lm in diameter), in the leptome-
ningeal arteries of BCAS-operated Tg-SwDI mice at
Fig. 2 Representative
photomicrographs of CMIs from
patients with CAA. a CMIs
(arrows) were present in the
temporal cortex in a patient with
CAA-related inﬂammation
(H&E staining). Vascular Ab
depositions (brown) and marked
vascular/perivascular inﬁltration
of inﬂammatory cells are shown
in insets (left, anti-Ab
immunostaining with
hematoxylin counterstain; right,
H&E staining). b, A CMI
(arrows) in the occipital cortex
in a patient with AD. c–e A
CMI was accompanied with
GFAP-positive reactive
astroglial cells and CD68-
positive macrophage/microglial
proliferation (adjacent sections;
c H&E; d GFAP; and e CD68).
Bars indicate 300 lmi na,
50 lmi nb, and 100 lmi n
c–e and insets in a
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12318 weeks of age; however, Ab accumulation in the lepto-
meningeal arteries were less apparent in sham-operated Tg-
SwDI mice at 18 or 24 weeks of age (Fig. 6b). As a result,
two-way ANOVA showed that BCAS had a signiﬁcant
[F (1, 25) = 18.5, p = 0.0002] effect on leptomeningeal
Ab accumulation. However, there was no effect of age on
leptomeningeal Ab accumulation [F (2, 25) = 1.73,
p = 0.20] (Fig. 6f), suggesting a ceiling effect of age on
leptomeningeal Ab accumulation.
By contrast, in the hippocampus and the cerebral cortex,
two-way ANOVA showed a signiﬁcant effect of age
[hippocampus, F (2, 25) = 15.8, p\0.0001; cortex, F (2,
25) = 7.02, p = 0.0038] but no effect of the operation
[hippocampus, F (1, 25) = 2.79, p = 0.11; cortex, F (1,
25) = 0.73, p = 0.40] on Ab accumulation (Fig. 6a, d, e).
In all Tg-SwDI mice combined, the amount of lepto-
meningeal Ab was signiﬁcantly greater in mice with
microinfarcts (3.4-fold), compared to those without micr-
oinfarcts (p = 0.0004). Most microinfarcts were seen in
the cortex (Fig. 5b) and close to the Ab-deposited vessels;
however, some microinfarcts were also seen in the hippo-
campus CA1 area in the 18, 24, and 32-week-old BCAS-
operated Tg-SwDI mice (Fig. 5d). A small number of
microhemorrhages were also detected in the ventral part of
the thalamus in the 32-week-old BCAS-operated Tg-SwDI
mice (Fig. 5e, f), although such changes were not found in
sham-operated Tg-SwDI mice or BCAS-operated wild-
type mice up to 32 weeks of age (Fig. 5a, c). Thrombus
formation was not apparent in any sections assessed.
Discussion
We found that CMI density is related to CAA severity, but
not to SP or NFT burden severity, suggesting that the
presence of Ab causes loss of vascular autoregulation
associated with rigidity of arterioles, leading to infarction in
the territory of their branching vessels. Thrombus formation
induced by endothelial damage in CAA may have also been
involved in the CMI development although the thrombus
Fig. 3 Representative
photomicrographs of CMIs
stained with H&E and Ab from
patients with CAA. a, b CMIs
were located in close proximity
to Ab-deposited vessels. a and
b are adjacent sections (a H&E;
b Ab). c Ab-positive senile
plaques were not apparent
inside a CMI (arrows). The
arrowhead indicates an Ab-
positive arteriole within a CMI.
Bars indicate 500 lmi na and
b, and 100 lmi nc
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123was found only in one patient with CAA but not in any
Tg-SwDI mice. The severity of white matter changes was
not associated with the CMI density, which may raise the
possibility that the CMIs and white matter changes have
different formation processes as white matter damage is
reported to reﬂect a progressive microangiopathy due to
CAA [10]. Furthermore, our study showed that CMI density
is no greater in AD than in other disorders accompanied
with CAA. Given that CMI is also a strong determinant for
dementia [23, 49], the observed correlation between CMI
and CAA strengthens the notion that, although underesti-
mated, these two pathologies are important substrates of
cognitive decline in the elderly [15, 16].
Previous studies have reported an association between
CMI and CAA in AD [15, 16, 34, 40], but others have
found no such link [12, 24]. Inconsistencies between dif-
ferent studies might be attributable to the heterogeneity of
underlying vascular pathology in AD as cerebrovascular
changes can occur concomitantly with AD pathology, and
also because CAA may contribute to the development of
various types of cerebrovascular diseases such as lobar
hemorrhage, microbleeds, and white matter lesions [39].
The issue is further complicated by the fact that CAA
usually accompanies AD, but does not exclusively result
from AD. Thus, accordingly, a signiﬁcant correlation has
been reported between the severity of CAA and the amount
of CMIs in only one other study using postmortem brains
of vascular dementia [16]. The current study, which used
an unbiased collection of brains including non-AD sam-
ples, conﬁrms the previous report and suggests that CAA
along with chronic cerebral hypoperfusion may give rise to
CMIs, which appear to be true substrates of cognitive
impairment [14]. This may explain the previous ﬁndings,
which have indicated that severity of CAA is associated
with increased frequency of antemortem cognitive decline
[25, 31]. Our ﬁndings, which show a strong association
between CMIs and CAA, are supported by additional ani-
mal studies using the Tg-SwDI mice subjected to chronic
cerebral hypoperfusion; when combined these ﬁndings
have demonstrated that cerebral hypoperfusion induces: (1)
accumulation of CAA-like vascular Ab and resultant vas-
cular compromise and (2) development of microinfarcts
and even microhemorrhages in a subset of animals. Since
microinfarcts did not develop in wild-type mice after
BCAS, the data suggest that both CAA and hypoperfusion
are required for microinfarct development. Tg-SwDI mice
may have morphological changes in the endothelium and in
the basement membranes of capillaries and arteries, lead-
ing to a failure of the mechanisms of clearance of Ab and
other metabolites. Hypoperfusion may interfere with the
arterial pulsations and with the interstitial ﬂuid pressure,
leading to reduced perivascular clearance of Ab as mani-
fested by CAA associated with microinfarcts.
We have previously shown that chronic cerebral hypo-
perfusion increased the amount of ﬁlter-trap Ab in the
extracellular-enriched soluble brain fraction of mice over-
expressing a mutant form of the human APP [22, 51]; in
this mouse model exhibiting senile plaques, the neuronal
loss and cognitive impairment that were both accelerated
by hypoperfusion was explained by the disturbed Ab
metabolism. In the current study using mice overexpressing
vasculotropic mutant Ab, the hypoperfusion-induced
aggravation of CAA may then result from increased syn-
thesis of Ab [45]. Alternatively, cerebral hypoperfusion
and reduced vascular pulsation may impede clearance of
Ab as it is hypothesized that motive force of vessel pul-
sation is required for perivascular clearance of interstitial
ﬂuid containing Ab [47]. This mechanism may temporarily
Table 2 Univariate analysis of variables
Factors N CMI density r value p value
Age (years) –0.2570 0.1627
\70 5 2.101
70–79 8 1.142
80–89 18 0.520
Atherosclerosis –0.0913 0.6312
Normal (0) 3 1.642
Mild (1) 19 0.916
Moderate (2) 6 0.898
Severe (3) 2 0.578
Disease –0.1007 0.5900
Non-AD (0) 17 1.118
AD (1) 14 0.714
CAA 0.6736 \0.0001
Mild (1) 17 0.112
Moderate (2) 9 0.584
Severe (3) 5 4.368
SP –0.2265 0.2204
None (0) 1 2.425
Sparse (1) 10 1.511
Moderate (2) 4 0.353
Frequent (3) 16 0.628
NFT –0.1378 0.4597
I (1) 2 0.086
II (2) 8 0.983
III (3) 1 10.353
IV (4) 12 0.641
V (5) 5 0.528
VI (6) 3 0.093
WML 0.1962 0.2902
Normal (0) 4 0.074
Mild (1) 16 0.790
Moderate (2) 10 1.567
Severe (3) 1 0.400
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Fig. 4 Correlation of CMI density with CAA severity. a A diagram
showing no signiﬁcant difference in CMI density between AD and
non-AD groups (*p = 0.5900). b A diagram showing CMI density in
each lobe of AD and non-AD groups combined. c Diagram showing
CMI density in each lobe of AD and non-AD groups. d Signiﬁcant
correlation of CMI density with CAA severity (*p\0.0001). e CAA-
CMI correlation was observed in each lobe. f CAA–CMI correlation
was observed in both AD and non-AD group. g CMI density was
not associated with SP burden (*p = 0.2204). h CMI density was not
associated with NFT stage (*p = 0.4597). i CMI density was not
associated with atherosclerosis grade (*p = 0.6312)
Table 3 Multivariate analysis
of variables
Variables Partial regression
coefﬁcient
Standard partial
regression coefﬁcient
t value p value Tolerance
CAA severity 1.7190 0.6395 3.4654 0.0022 0.4220
NFT stage 0.3019 0.2168 0.8825 0.3870 0.3555
Atherosclerosis grade -0.4188 -0.1483 -0.8632 0.3973 0.7284
SP burden -0.4848 -0.2346 -0.6596 0.5164 0.1723
Age -0.0244 -0.0968 -0.5352 0.5979 0.6704
WML grade 0.1970 0.0698 0.3999 0.6931 0.7247
Disease -0.2555 -0.0626 -0.2090 0.8364 0.2468
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123aggravate CAA, which may compromise cerebral perfusion
and ultimately lead to development of microinfarcts. Thus,
the impaired microvascular function observed may impede
perivascular drainage pathway of Ab, forming a cycle of
vascular Ab deposition.
Our ﬁndings may also have implications in the under-
standing of the pathological complications of Ab
immunotherapy. The hypoperfusion-induced abnormalities
seen in Tg-SwDI mice may be similar to the ﬁndings in AD
patients who have received Ab immunotherapy; in immu-
nized AD group, microvascular lesions, such as CMIs or
microhemorrhages, occurred with a higher density than
non-immunized AD control group; this may have been
because soluble Ab mobilized from the amyloid deposits
had not cleared efﬁciently from AD brains [6, 35]. It is
plausible that the aging- and AD-associated microvascular
changes [18] cannot cope with overwhelming amount of
Ab mobilized from the Ab deposits at least partially due to
existing reduction of vessel pulsation and/or hypoper-
fusion, leading to formation of CMIs or microhemorrhages
in immunized AD patients. The current study indicates that
such mechanisms underlie the formation of CMIs, even in
Fig. 5 Appearance of
microinfarcts and
microhemorrhages in Tg-SwDI
mice after cerebral
hypoperfusion. a–
e Representative
photomicrographs of H&E
staining showing that following
BCAS-induced cerebral
hypoperfusion, a cortical
microinfarct developed at
18 weeks of age in three of six
Tg-SwDI mice (b), a
hippocampal microinfarct at
24 weeks of age in three of
seven Tg-SwDI mice (d), and a
striatal microhemorrhage at
32 weeks of age in one of four
Tg-SwDI mice (e), although
such changes were not found in
sham-operated Tg-SwDI mice
at indicated time points (a, c).
f Perls-Stieda’s iron staining
showing the striatal
microhemorrhage. Bars indicate
200 lmi na–d and 40 lmi n
e and f
Fig. 6 Enhanced Ab deposition in Tg-SwDI mice after cerebral
hypoperfusion. a Ab immunohistochemical staining showing that
followingcerebralhypoperfusion,Tg-SwDImiceexhibitedcorticalAb
deposition at 24 weeks of age (right middle panel) and more
extensively at 32 weeks of age (right lower panel). Sham-operated
Tg-SwDI mice showed cortical Ab deposition at 32 weeks of age (left
lower panel). Insets show representative images of vascular and
perivascular Ab deposition. b Ab immunohistochemical staining
showing that following cerebral hypoperfusion, Tg-SwDI mice exhib-
ited Ab deposition in the leptomeninges containing leptomeningeal
arteries (arrows) at 18 weeks of age (right upper panel) and more
extensively at 24 and 32 weeks of age (right middle and lower panels),
although sham-operated Tg-SwDI mice began to show such changes at
32 weeksofage(leftlowerpanel).Insetsshowrepresentativeimagesof
vascular and perivascular Ab deposition in the leptomeningeal artery.
In a and b, the mouse anti-Ab1–40 (BA27) antibody was used. c The
schematic illustration of the regions of interest depicted in the cerebral
cortex (size, 500 9 300 lm each), the hippocampus (500 9 300 lm
each), and the leptomeninges including the pia and arteries
(300 9 50 lm each) of the parasagittal section of the brain. d–
f Densitometric analyses of temporal proﬁles of Ab depositions in the
cerebral cortex (d), the hippocampus (e), and the leptomeninges (f).
Leptomeningeal vascular, as well as pial, Ab accumulation was jointly
analyzed as ‘leptomeningeal Ab’. There seems to be a ceiling effect of
age on leptomeningeal Ab accumulation. CPu caudoputamen, Cx
cortex, Hip hippocampus, LM leptomeninge, LV lateral ventricle, Thal
thalamus. Bars indicate 40 lmi na and b and 8 lm in insets in a and b
c
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123non-immunized patients with CAA. The degree of hypo-
perfusion and microvascular changes may predict the
response rate of Ab immunotherapy and the emergence
rate of ischemic complications. However, it remains to be
determined whether chronic cerebral hypoperfusion ham-
pers the Ab drainage pathway directly through reduced
arterial pulsation or indirectly through upregulated Ab
synthesis.
The main limitation of this study is the lack of clinical
and neuropsychometric information on the postmortem
brains used. This meant that we could not directly relate
our pathological ﬁndings to antemortem hypoperfusive and
cognitive status. Another limitation is that CAA or CMI
severity could not be related to the apolipoprotein E
genotype [36], due to ethical and legal constraints of
genotype extraction. In addition, the use of the CERAD
392 Acta Neuropathol (2012) 123:381–394
123criteria for assessing the burden of neuritic plaques and the
Braak staging for the burden of NFTs both based on the
modiﬁed Bielschowsky staining may be the third limita-
tion, considering that the CERAD is semiquantitative
rather than quantitative measures of neuropathology [28]
and the Braak staging criteria for tau pathology have been
recently modiﬁed [2], although the two neuropathologists
agreed on their ﬁnal grading of the 31 CAA patients
enrolled in the current study.
In summary, using postmortem brain analysis of rele-
vant patients and models of transgenic mice, our study
provides strong evidence for the relationship between CAA
and microinfarcts with cerebral hypoperfusion as the
mediating factor. Our observations support the notion that
CAA is one of the pathological substrates that links
neurodegenerative and vascular processes.
Acknowledgments We would like to express our cordial gratitude
to Ms. Takako Kawada and Ms. Mayumi Ohara for their excellent
technical assistance, and Dr. Ahmad Khundakar for his critical
reading of the manuscript. We gratefully acknowledge grant support
from the Lifelong Health & Wellbeing programme supported by the
Research Councils UK Newcastle Centre for Brain Ageing and
Vitality (R.N.K.), Alzheimer’s Research UK (R.N.K.), the UK NIHR
Biomedical Research Centre for Ageing and Age Related Diseases
award to the Newcastle upon Tyne Hospitals NHS Foundation Trust
(R.N.K.), the Bayer Scholarship for Cardiovascular Research (M.I.),
the Univers Foundation (M.I.), and the Grants-in-Aid for Scientiﬁc
Research (B) (M.I. No. 23390233).
Conﬂict of interest The authors have no conﬂict of interest to
declare.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Budka H (1998)
Blood–brain barrier dysfunction in Binswanger’s disease; an
immunohistochemical study. Acta Neuropathol 95:78–84
2. Alafuzoff I, Arzberger T, Al-Sarraj S et al (2008) Staging of
neuroﬁbrillary pathology in Alzheimer’s disease: a study of the
BrainNet Europe Consortium. Brain Pathol 18:484–496
3. American Psychiatric Association (1994) Diagnostic and statis-
tical manual of mental disorders, 4th edn. American Psychiatric
Press, Washington, DC
4. Attems J, Jellinger K, Thal DR, Van Nostrand W (2011) Review:
sporadic cerebral amyloid angiopathy. Neuropathol Appl Neu-
robiol 37:75–93
5. Bennett DA, Wilson RS, Gilley DW, Fox JH (1990) Clinical
diagnosis of Binswanger’s disease. J Neurol Neurosurg Psychi-
atry 53:961–965
6. Boche D, Zotova E, Weller RO et al (2008) Consequence of
Abeta immunization on the vasculature of human Alzheimer’s
disease brain. Brain 131:3299–3310
7. Braak H, Braak E (1991) Neuropathological stageing of Alzhei-
mer-related changes. Acta Neuropathol 82:239–259
8. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K
(2006) Staging of Alzheimer disease-associated neuroﬁbrillary
pathology using parafﬁn sections and immunocytochemistry.
Acta Neuropathol 112:389–404
9. Brun A, Englund E (1986) A white matter disorder in dementia of
the Alzheimer type: a pathoanatomical study. Ann Neurol 19:
253–262
10. Chen YW, Gurol ME, Rosand J et al (2006) Progression of white
matter lesions and hemorrhages in cerebral amyloid angiopathy.
Neurology 67:83–87
11. Davis J, Xu F, Deane R et al (2004) Early-onset and robust
cerebral microvascular accumulation of amyloid beta-protein in
transgenic mice expressing low levels of a vasculotropic Dutch/
Iowa mutant form of amyloid beta-protein precursor. J Biol Chem
279:20296–20306
12. Ellis RJ, Olichney JM, Thal LJ et al (1996) Cerebral amyloid
angiopathy in the brains of patients with Alzheimer’s disease: the
CERAD experience, part XV. Neurology 46:1592–1596
13. Grinberg LT, Thal DR (2010) Vascular pathology in the aged
human brain. Acta Neuropathol 119:277–290
14. Hachinski V, Iadecola C, Petersen RC et al (2006) National
Institute of Neurological Disorders and Stroke–Canadian Stroke
Network vascular cognitive impairment harmonization standards.
Stroke 37:2220–2241
15. Haglund M, Sjobeck M, Englund E (2004) Severe cerebral
amyloid angiopathy characterizes an underestimated variant
of vascular dementia. Dement Geriatr Cogn Disord 18:
132–137
16. Haglund M, Passant U, Sjobeck M, Ghebremedhin E, Englund E
(2006) Cerebral amyloid angiopathy and cortical microinfarcts as
putative substrates of vascular dementia. Int J Geriatr Psychiatry
21:681–687
17. Ihara M, Polvikoski TM, Hall R et al (2010) Quantiﬁcation of
myelin loss in frontal lobe white matter in vascular dementia,
Alzheimer’s disease, and dementia with Lewy bodies. Acta
Neuropathol 119:579–589
18. Kalaria RN (1996) Cerebral vessels in ageing and Alzheimer’s
disease. Pharmacol Ther 72:193–214
19. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski
T (2004) Towards deﬁning the neuropathological substrates of
vascular dementia. J Neurol Sci 226:75–80
20. Kalaria RN, Thomas A, Oakley A et al (2003) Cerebrovascular
amyloidosis and dementia. Curr Med Chem Immunol Endocr
Metab Agents 3:317–327
21. Kawamoto Y, Akiguchi I, Nakamura S, Budka H (2002) Accu-
mulation of 14-3-3 proteins in glial cytoplasmic inclusions in
multiple system atrophy. Ann Neurol 52:722–731
22. Kitaguchi H, Tomimoto H, Ihara M et al (2009) Chronic cerebral
hypoperfusion accelerates amyloid beta deposition in APPSwInd
transgenic mice. Brain Res 1294:202–210
23. Kovari E, Gold G, Herrmann FR et al (2004) Cortical microin-
farcts and demyelination signiﬁcantly affect cognition in brain
aging. Stroke 35:410–414
24. Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR
(2008) AD brain pathology: vascular origins? Results from the
HAAS autopsy study. Neurobiol Aging 29:1587–1590
25. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P
(2009) Epidemiological pathology of dementia: attributable-risks
at death in the Medical Research Council Cognitive Function and
Ageing Study. PLoS Med 6:e1000180
26. McCarran WJ, Goldberg MP (2007) White matter axon vulner-
ability to AMPA/kainate receptor-mediated ischemic injury is
developmentally regulated. J Neurosci 27:4220–4229
27. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and
management of dementia with Lewy bodies: third report of the
DLB Consortium. Neurology 65:1863–1872
Acta Neuropathol (2012) 123:381–394 393
12328. Mirra SS, Gearing M, McKeel DW Jr et al (1994) Interlaboratory
comparison of neuropathology assessments in Alzheimer’s dis-
ease: a study of the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD). J Neuropathol Exp Neurol 53:
303–315
29. Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD). Part II.
Standardization of the neuropathologic assessment of Alzhei-
mer’s disease. Neurology 41:479–486
30. Nakaji K, Ihara M, Takahashi C et al (2006) Matrix metallo-
proteinase-2 plays a critical role in the pathogenesis of white
matter lesions after chronic cerebral hypoperfusion in rodents.
Stroke 37:2816–2823
31. Neuropathology Group. Medical Research Council Cognitive
Function Aging Study (2001) Pathological correlates of late-onset
dementia in a multicentre, community-based population in Eng-
land and Wales. Neuropathology Group of the Medical Research
Council Cognitive Function and Ageing Study (MRC CFAS).
Lancet 357:169–175
32. Nishio K, Ihara M, Yamasaki N et al (2010) A mouse model
characterizing features of vascular dementia with hippocampal
atrophy. Stroke 41:1278–1284
33. Okamoto Y, Ihara M, Fujita Y, Ito H, Takahashi R, Tomimoto H
(2009) Cortical microinfarcts in Alzheimer’s disease and sub-
cortical vascular dementia. Neuroreport 20:990–996
34. Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman
R, Thal LJ (1995) Cerebral infarction in Alzheimer’s disease is
associated with severe amyloid angiopathy and hypertension.
Arch Neurol 52:702–708
35. Patton RL, Kalback WM, Esh CL et al (2006) Amyloid-beta
peptide remnants in AN-1792-immunized Alzheimer’s disease
patients: a biochemical analysis. Am J Pathol 169:1048–1063
36. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN
(1996) Apolipoprotein E-epsilon4 alleles in cerebral amyloid
angiopathy and cerebrovascular pathology associated with
Alzheimer’s disease. Am J Pathol 148:2083–2095
37. Shibata M, Ohtani R, Ihara M, Tomimoto H (2004) White matter
lesions and glial activation in a novel mouse model of chronic
cerebral hypoperfusion. Stroke 35:2598–2603
38. Shibata M, Yamasaki N, Miyakawa T et al (2007) Selective
impairment of working memory in a mouse model of chronic
cerebral hypoperfusion. Stroke 38:2826–2832
39. Smith EE, Greenberg SM (2009) Beta-amyloid, blood vessels,
and brain function. Stroke 40:2601–2606
40. Soontornniyomkij V, Lynch MD, Mermash S et al (2010) Cere-
bral microinfarcts associated with severe cerebral beta-amyloid
angiopathy. Brain Pathol 20:459–467
41. Suter OC, Sunthorn T, Kraftsik R et al (2002) Cerebral
hypoperfusion generates cortical watershed microinfarcts in
Alzheimer disease. Stroke 33:1986–1992
42. Thal DR, Grifﬁn WS, de Vos RA, Ghebremedhin E (2008)
Cerebral amyloid angiopathy and its relationship to Alzheimer’s
disease. Acta Neuropathol 115:599–609
43. Underhill SM, Goldberg MP (2007) Hypoxic injury of isolated
axons is independent of ionotropic glutamate receptors. Neuro-
biol Dis 25:284–290
44. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird
ED, Richardson EP Jr (1991) Cerebral amyloid angiopathy
without and with cerebral hemorrhages: a comparative histolog-
ical study. Ann Neurol 30:637–649
45. Wang Z, Wu D, Vinters HV (2002) Hypoxia and reoxygenation
of brain microvascular smooth muscle cells in vitro: cellular
responses and expression of cerebral amyloid angiopathy-asso-
ciated proteins. APMIS 110:423–434
46. Weller RO, Boche D, Nicoll JA (2009) Microvasculature changes
and cerebral amyloid angiopathy in Alzheimer’s disease and their
potential impact on therapy. Acta Neuropathol 118:87–102
47. Weller RO, Djuanda E, Yow HY, Carare RO (2009) Lymphatic
drainage of the brain and the pathophysiology of neurological
disease. Acta Neuropathol 117:1–14
48. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM,
Roher AE (1998) Cerebral amyloid angiopathy: amyloid beta
accumulates in putative interstitial ﬂuid drainage pathways in
Alzheimer’s disease. Am J Pathol 153:725–733
49. White L, Petrovitch H, Hardman J et al (2002) Cerebrovascular
pathology and dementia in autopsied Honolulu-Asia Aging Study
participants. Ann N Y Acad Sci 977:9–23
50. Wyss-Coray T, Lin C, Yan F et al (2001) TGF-beta1 promotes
microglial amyloid-beta clearance and reduces plaque burden in
transgenic mice. Nat Med 7:612–618
51. Yamada M, Ihara M, Okamoto Y et al (2011) The inﬂuence of
chronic cerebral hypoperfusion on cognitive function and amy-
loid beta metabolism in APP overexpressing mice. PLoS One 6:
e16567
52. Yamamoto T, Hirano A (1986) A comparative study of modiﬁed
Bielschowsky, Bodian and thioﬂavin S stains on Alzheimer’s
neuroﬁbrillary tangles. Neuropathol Appl Neurobiol 12:3–9
394 Acta Neuropathol (2012) 123:381–394
123